DLH Holdings (DE:TS8A)
FRANKFURT:TS8A
TS8A Stock Chart & Stats
€5.00
-€0.35(-4.52%)
At close: 4:00 PM EST
€5.00
-€0.35(-4.52%)
Day’s Range― - ―
52-Week Range€4.42 - €6.90
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€70.16M
Enterprise Value€226.75M
Total Cash (Recent Filing)€131.00K
Total Debt (Recent Filing)€145.58M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 05, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding14,493,035
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)0.72
Price to Sales (P/S)0.24
P/FCF Ratio3.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.59Price Target Upside71.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€200.22M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationSustained positive operating and free cash flow (~$19M TTM) gives DLH durable internal liquidity to fund operations, service debt, and invest selectively. Even with net losses, consistent cash conversion supports deleveraging and cushions timing mismatches in federal procurement cycles.
Deleveraging And Covenant ComplianceManagement’s active debt reduction (debt down QoQ and plan to convert 50–55% of EBITDA to debt paydown) demonstrates discipline that strengthens long-term financial flexibility, reduces covenant risk, and improves capacity to absorb contract lulls inherent in government services businesses.
Sole‑source NIH Extension And Pipeline VisibilityA two‑year sole‑source NIH extension provides multi-year revenue visibility in DLH’s core federal health niche, reinforcing customer relationships and recurring revenue potential. Coupled with management’s cited improving pipeline, this helps offset concentration shocks from other contract transitions.
Bears Say
Steep Revenue DeclineA roughly one‑third YoY revenue drop reflects material loss of program volume and reduces operating leverage. Persistently lower revenue would pressure margins, cash flow trajectory, and the company's ability to rebuild scale in federal health services amid competitive recompetes and set‑aside dynamics.
Elevated LeverageDespite recent paydowns, materially elevated debt-to-equity (~1.3x TTM) and negative ROE limit strategic flexibility. If revenue and net income remain pressured, servicing and reducing leverage could crowd out investments or force sharper cost cutting, constraining long‑term growth execution.
Contract Concentration & Set‑aside TransitionsConversion of legacy work (e.g., VA CMOP) to small business set‑asides is a structural revenue loss that reduces the company’s addressable workload and predictability. Combined with procurement timing and protest risks, this raises the odds of prolonged revenue volatility during recompetes.
DLH Holdings News
TS8A FAQ
What was DLH Holdings’s price range in the past 12 months?
DLH Holdings lowest stock price was €4.42 and its highest was €6.90 in the past 12 months.
What is DLH Holdings’s market cap?
DLH Holdings’s market cap is €70.16M.
When is DLH Holdings’s upcoming earnings report date?
DLH Holdings’s upcoming earnings report date is Aug 05, 2026 which is in 58 days.
How were DLH Holdings’s earnings last quarter?
DLH Holdings released its earnings results on May 06, 2026. The company reported -€0.145 earnings per share for the quarter, missing the consensus estimate of -€0.136 by -€0.009.
Is DLH Holdings overvalued?
According to Wall Street analysts DLH Holdings’s price is currently Undervalued.
Does DLH Holdings pay dividends?
DLH Holdings does not currently pay dividends.
What is DLH Holdings’s EPS estimate?
DLH Holdings’s EPS estimate is -0.14.
How many shares outstanding does DLH Holdings have?
DLH Holdings has 14,493,035 shares outstanding.
What happened to DLH Holdings’s price movement after its last earnings report?
DLH Holdings reported an EPS of -€0.145 in its last earnings report, missing expectations of -€0.136. Following the earnings report the stock price went down -0.422%.
Which hedge fund is a major shareholder of DLH Holdings?
Currently, no hedge funds are holding shares in DE:TS8A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DLH Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€8.59 (71.75% Upside)
€8.59 (71.75% Upside)
Insider Transactions
Bought Shares
Worth €423.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.72%
12-Months-Change
Fundamentals
Return on Equity
-4.00%
Trailing 12-Months
Asset Growth
-9.75%
Trailing 12-Months
Company Description
DLH Holdings
DLH Holdings Corp., headquartered in Atlanta, Georgia, was established in 1969 and operated as TeamStaff, Inc. until its name change in June 2012. The company specializes in offering a range of technology-enabled business process outsourcing, comprehensive program management solutions, and public health research and analytics services throughout the United States, with a primary focus on the federal health services market. A significant portion of DLH's work involves defense and veterans' health, where it delivers integrated healthcare, technology, and logistical support. Key clients in this sector include the Department of Veterans Affairs (VA), the Defense Health Agency, the Tele-medicine and Advanced Technology Research Center, the Navy Bureau of Medicine and Surgery, and the Army Medical Research and Material Command. Additionally, the company provides diverse human services and solutions, covering areas such as rigorous monitoring and evaluation, efficient electronic medical records migration, robust data collection and management, and thorough nutritional and social health assessments. It also offers expert IT system architecture design, strategic migration planning, and continuous maintenance services. In the sphere of public health and life sciences, DLH undertakes crucial initiatives like clinical trials, epidemiological studies, and disease prevention. It actively promotes health among underserved and at-risk communities through the creation of impactful strategic communication campaigns, research into emerging health trends, in-depth health informatics analyses, and the application of proven best practices.
TS8A Company Deck
TS8A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated a mixed picture: material near-term financial headwinds with a steep year-over-year revenue decline (~33.5%) and a sharp drop in adjusted EBITDA (~43.6%), largely driven by program transitions to small business set-asides and contract completions. Offsetting these negatives, management reported margin resilience (9% adjusted EBITDA margin), positive free cash flow (~$3.8M), resumed deleveraging (debt reduced to $132.7M), a two-year NIH contract extension adding revenue visibility, recognition for technology capabilities, and an improving pipeline as delayed procurements return to market. Risks remain around federal health reprioritization and typical government procurement timing uncertainty, but the company appears to be stabilizing its cost structure and positioning for upcoming opportunities.View all DE:TS8A earnings summariesTS8A Stock 12 Month Forecast
Average Price Target
€8.59
▲(71.75% Upside)
Technical Analysis
Options Prices
Currently, No data available
---